Discussions on the procurement of a COVID19 vaccine candidate
Grant, Contribution or Other Financial Benefit, Policies or Program
Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.
Legislative Proposal, Bill or Resolution, Regulation
Monitoring and engaging on the Act respecting certain measures in response to COVID-19 and the changes to the Patent Act, including eventual regulations and guidelines, formally known as Bill C-13, An Act respecting certain measures in response to COVID-19 .
Policies or Program
Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries
Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages and discussion on COVID19 potential impacts
Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for high-cost drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare.
Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED).
The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.
Policies or Program, Regulation
Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.
Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.